Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
IRVINE, Calif. - CG Oncology, Inc. (NASDAQ:CGON), a clinical-stage biotechnology company with a market capitalization of $2.06 billion, reported significant progress in its Phase 3 study of cretostimogene, an investigational bladder cancer treatment. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet, though current analysis suggests the stock is trading above its Fair Value. The study, which involved 110 patients with high-risk non-muscle invasive bladder cancer unresponsive to BCG therapy, showed that 75.5% achieved a complete response at some point during the trial.
The data, presented at the European Association of Urology Congress, indicated a median duration of response exceeding 28 months, with 46% of patients in complete response at 12 months and 30 confirmed responses at 24 months. The study, known as BOND-003, did not reach a median duration of response, suggesting ongoing effectiveness of the treatment.
Cretostimogene, delivered intravesically, peaked in concentration immediately after instillation and remained locally for 4-5 days without systemic exposure. This finding is critical as it implies that patients would not require close contact precautions post-treatment, a significant consideration for patient quality of life.
The safety profile of cretostimogene was also notable, with no Grade 3 or greater treatment-related adverse events or deaths reported. The most common treatment-related adverse events were minor and included bladder spasm and hematuria, with a median resolution time of one day.
Dr. Trinity J. Bivalacqua from the Perelman Center for Advanced Medicine at the University of Pennsylvania highlighted the treatment’s strong safety and efficacy profile, suggesting that cretostimogene could represent a breakthrough in bladder cancer treatment if approved by the FDA. Wall Street appears optimistic about the company’s prospects, with InvestingPro analysts setting price targets ranging from $55 to $83, and forecasting significant revenue growth of 332% for the current fiscal year.
Ambaw Bellete, President & Chief Operating Officer of CG Oncology, expressed gratitude to patients and providers participating in the study and optimism about cretostimogene’s potential impact on bladder cancer care.
Cretostimogene is also being evaluated in other clinical trials, including a Phase 3 monotherapy trial and an investigator-sponsored trial in combination with nivolumab for muscle invasive bladder cancer.
While the results are promising, cretostimogene’s safety and efficacy have not yet been established by the FDA or any other health authority. The company cautions that the forward-looking statements regarding cretostimogene’s potential benefits are based on current beliefs and expectations and are subject to risks and uncertainties that could cause actual results to differ. InvestingPro analysis reveals the company maintains excellent liquidity with a current ratio of 35.32, though it currently operates with negative profit margins. Investors can access comprehensive financial analysis and additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks including CGON.
This article is based on a press release statement from CG Oncology.
In other recent news, CG Oncology announced revised employment agreements for its key executives, including the CEO and President/COO. These new agreements enhance severance benefits and equity vesting conditions in cases of termination without cause or during a change in control period. The agreements include lump sum payments, COBRA premium payments, and prorated annual bonuses, with specific terms varying based on the timing of termination. Additionally, similar amendments were made for the Chief Medical Officer, Chief Financial Officer, and General Counsel, offering severance benefits and equity vesting provisions.
Analysts at TD Cowen have initiated coverage on CG Oncology with a Buy rating, indicating confidence in the company’s future prospects. This optimism is largely attributed to the potential of CG Oncology’s product, Creto, which is anticipated to be effective for patients with high-risk non-muscle invasive bladder cancer. The analysts project that Creto could generate $2.5 billion in revenue by 2035. The coverage initiation by TD Cowen underscores a positive outlook for CG Oncology’s strategic direction and its focus on addressing unmet medical needs in bladder cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.